This article only represents the author's own views.
A wave of potentially lucrative licensing deals has swept across China’s biopharma sector in recent months, but investors have not been impressed.
From RemeGen in July to InnoCare Pharma and Hansoh Pharmaceutical in October, several Chinese drug developers have made high-value announcements about overseas partnerships, only to be met with muted market reactions.
您已閱讀7%（415字），剩余93%（5750字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。